HOME >> BIOLOGY >> NEWS
'Meeting of the minds' leads new era in fight against cancer

Orlando, Fla. Leading researchers are gathering today for the 95th Annual Meeting of the American Association for Cancer Research (AACR), the premier multidisciplinary assembly, which features the latest developments in basic, prevention, translational and clinical cancer research. The meeting occurs from March 27 31, 2004 at the Orlando Convention Center, Fla.

"Because scientific advances are pushing forward at such an incredible pace, our insight into cancer mechanism and progression is growing exponentially," said Karen Antman, M.D., president of AACR. "The AACR Annual Meeting will help us harness this information to develop and discover cutting-edge diagnostics and treatments necessary to conquer this disease."

This year's Annual Meeting will spotlight new information and innovations that are leading to a new understanding of cancer and its course of action. Presentations by top scientists will include novel technologies and research approaches, lifesaving therapies in the pipeline, and new insights into prevention.

"Thanks to persistence and determination on part of the researchers, we can better understand the intricacies of cancer that will ultimately lead to its cure," said Dr. Antman.

The discussions presented during the opening plenary session, Targeting the Conquest of Cancer through Conceptual Integration and Innovation (Sunday, March 28, 9:30 a.m. to 12:00 p.m.), reflect the theme of this year's Annual Meeting Information Integration for Innovation.

Researchers will present a broad range of discoveries in the field of cancer research, including an in-depth review of telomerase, a DNA shield which may be central to cancer progression, followed by a continued investigation into the impact of COX-2. The increasingly important area of genomics also will be highlighted by researchers who will discuss the identification of undiscovered gene functions as potential targets for the development of anti-cancer dr
'"/>

Contact: Aimee Frank
amf@spectrumscience.com
202-955-6222
American Association for Cancer Research
27-Mar-2004


Page: 1 2

Related biology news :

1. Loss of the neuronal adhesion protein d-catenin leads to severe cognitive dysfunction
2. Cockroach-like robot leads new research effort
3. Washington University in St. Louis leads group studying aging process
4. Green tea research leads to gum and other products
5. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
6. Research into cetacean reproduction leads to birth of killer whales by artificial insemination
7. UCSD finds genetic time bomb in heart that leads to heart failure in some patients
8. Delirium high in ICU patients, leads to death, morbidity
9. Gene mutation leads to super-virulent strain of TB
10. Researchers show absence of key oxygen-sensing molecule leads to developmental defects
11. Ten-year study leads researchers to psoriasis genes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Meeting the minds leads new era fight against cancer

(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/18/2015)... 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market announces that its Wocket® smart ... "Money on the Mark", scheduled to air on WABC Radio ... 20 th . The broadcast air- time ... to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today ... Convention in Philadelphia, PA. , The presentation took place on Tuesday, June ... plans for the development of APX3330 for the treatment of pancreatic cancer. A ...
(Date:6/30/2015)... 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced ... Resverlogix have approved the resolutions relating to: (i) ... 5,600,000 units at a price of $2.67 per ... comprised of one common share and 0.075358 common ... CAD$15 million; and (ii) the amendment to Resverlogix,s ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome ... new insights on mechanics of fecal microbiota transplantation in C. difficile patients. , ... microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
Cached News: